Ετικέτες

Πέμπτη 2 Αυγούστου 2018

Prognostic Subgroups for Survival Outcomes in BRAF V600–Mutated Metastatic Melanoma

This exploratory recursive partitioning analysis modeled associations between prespecified covariates and survival outcomes using pooled data from 4 randomized clinical trials of adult patients with BRAF V600–mutated metastatic melanoma treated with dacarbazine, vemurafenib, or cobimetinib plus vemurafenib.

https://ift.tt/2LKehl8

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αναζήτηση αυτού του ιστολογίου